References

Cancer statistics, 2023

10.3322/caac.21763 · 2023 · External reference

Unresolved reference

External reference

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

10.1016/j.annonc.2024.10.018 · 2025 · External reference

Molecular portraits of human breast tumours

10.1038/35021093 · 2000 · External reference

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer

10.1200/jco.2012.43.4134 · 2013 · External reference

Systemic therapy for early-stage breast cancer: learning from the past to build the future

10.1038/s41571-022-00687-1 · 2022 · External reference

Residual cancer bur-den after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

10.1016/s1470-2045(21)00589-1 · 2022 · External reference

Standardized definitions for efficacy end points in ne-oadjuvant breast cancer clinical trials: NeoSTEEP

10.1200/jco.23.00435 · 2023 · External reference

Neoadjuvant chemotherapy and nodal response rates in luminal breast cancer: effects of age and tumor Ki67

10.1245/s10434-022-11871-z · 2022 · External reference

Defining the benefits of neoadjuvant chemotherapy for breast cancer

10.1200/jco.2011.41.3161 · 2012 · External reference

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes

10.1200/jco.2011.38.8595 · 2012 · External reference

10.1016/s0140-6736(13)62422-8

10.1016/s0140-6736(13)62422-8 · External reference

Pathologic complete response after neoadjuvant chemo-therapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis

10.1158/1078-0432.ccr-19-3492 · 2020 · External reference

Impact of estrogen receptor expression level on re-sponse to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

10.1186/s12885-023-11368-2 · 2023 · External reference

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer

10.1093/annonc/mdx397 · 2017 · External reference

10.1016/s0140-6736(20)32381-3

10.1016/s0140-6736(20)32381-3 · External reference

Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer

10.1002/cam4.4517 · 2022 · External reference

Comparing survival outcomes between neoadjuvant and ad-juvant chemotherapy within T2N1M0 stage hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study based on SEER database

10.1007/s12282-024-01583-5 · 2024 · External reference

Prognoses of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadju-vant chemotherapy before surgery: a retrospective analysis

10.3390/cancers15041157 · 2023 · External reference

Factors affecting pathologic complete remission in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadjuvant chemotherapy

10.1159/000526155 · 2022 · External reference

New and important changes in the TNM Staging sys-tem for breast cancer

10.1200/edbk_201313 · 2018 · External reference

Unresolved reference

External reference

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

10.1093/annonc/mdt303 · 2013 · External reference

HER2 amplification ratios by fluorescence in situ hy-bridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

10.3816/cbc.2004.n.011 · 2004 · External reference

Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update

10.1200/jco.2018.77.8738 · 2018 · External reference